- Home
- AWI vs GRFS Comparison
AWI vs GRFS Comparison
Compare AWI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWI
- GRFS
- Stock Information
- Founded
- AWI 1860
- GRFS 1940
- Country
- AWI United States
- GRFS Spain
- Employees
- AWI N/A
- GRFS N/A
- Industry
- AWI Plastic Products
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- AWI Industrials
- GRFS Health Care
- Exchange
- AWI Nasdaq
- GRFS Nasdaq
- Market Cap
- AWI 6.7B
- GRFS 5.5B
- IPO Year
- AWI 2006
- GRFS 2006
- Fundamental
- Price
- AWI $142.76
- GRFS $7.51
- Analyst Decision
- AWI Buy
- GRFS Strong Sell
- Analyst Count
- AWI 6
- GRFS 1
- Target Price
- AWI $140.83
- GRFS N/A
- AVG Volume (30 Days)
- AWI 197.7K
- GRFS 1.3M
- Earning Date
- AWI 02-18-2025
- GRFS 01-01-0001
- Dividend Yield
- AWI 0.86%
- GRFS N/A
- EPS Growth
- AWI 13.35
- GRFS N/A
- EPS
- AWI 5.66
- GRFS 0.27
- Revenue
- AWI $1,390,300,000.00
- GRFS $7,814,096,584.00
- Revenue This Year
- AWI $11.49
- GRFS $8.86
- Revenue Next Year
- AWI $6.99
- GRFS $7.00
- P/E Ratio
- AWI $25.22
- GRFS $33.24
- Revenue Growth
- AWI 7.99
- GRFS 7.21
- 52 Week Low
- AWI $95.24
- GRFS $5.30
- 52 Week High
- AWI $164.40
- GRFS $12.15
- Technical
- Relative Strength Index (RSI)
- AWI 30.06
- GRFS 44.79
- Support Level
- AWI $152.56
- GRFS $7.41
- Resistance Level
- AWI $152.56
- GRFS $8.13
- Average True Range (ATR)
- AWI 3.32
- GRFS 0.31
- MACD
- AWI -2.39
- GRFS 0.06
- Stochastic Oscillator
- AWI 11.46
- GRFS 45.13
About AWI Armstrong World Industries Inc
Armstrong World Industries Inc is engaged in the design, innovation and manufacture of ceiling and wall solutions in the Americas. The products include mineral fiber, fiberglass wool, metal, wood, wood fiber, glass-reinforced-gypsum and felt. The company also manufactures ceiling suspension system (grid) products through a joint venture with Worthington Industries, Inc. called Worthington Armstrong Venture (WAVE).
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.